Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.

Chengjun Sun,Biao Lu, Yu Liu,Yaqin Zhang, Haiyan Wei,Xu Hu, Pei Hu,Qian Zhao,Yanling Liu, Kan Ye,Kan Wang, Zaiyan Gu, Zheng Liu, Jin Ye, Hongxiao Zhang,Hong Zhu,Zhihong Jiang, Yanjie Liu,Naijun Wan, Chengming Yan, Jianying Yin, Lirong Ying, Feng Huang, Qingjin Yin,Li Xi, Feihong Luo,Ruoqian Cheng

Frontiers in endocrinology(2021)

引用 5|浏览5
暂无评分
摘要
[This corrects the article DOI: 10.3389/fendo.2021.779365.].
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要